Experimental studies in animal models have shown that the efficacy of anti‐PD‐1 therapy in tumor‐bearing mice largely depends on microbiome‐derived hexa‐acylated lipopolysaccharide (LPS) [125]. Here, PDCD1 is linked to neoplasm.